Acquired haemophilia A after alemtuzumab therapy

Marieke van der Zwan*, Frank W.G. Leebeek, Yorick Sandberg, Marieke J.H.A. Kruip, Dennis A. Hesselink

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

5 Citations (Scopus)
20 Downloads (Pure)
Original languageEnglish
Pages (from-to)e337-e339
Issue number6
Publication statusPublished - Nov 2020

Bibliographical note

Funding Information:
MvdZ declares no conflicts of interest. FWGL received research funding from CSL Behring, Shire/Takeda and uniQure. He is consultant for Biomarin, uniQure and Takeda of which fees got to the institution and is a DSMB member for Roche. MJHAK has received unrestricted research grants form Daiichi Sankyo, Boehringer Ingelheim, Bayer and Pfizer and speakers fee from Bayer. DAH has received grant support, lecture and consulting fees from Astellas Pharma and Chiesi Pharmaceuticals, as well as a lecture fee from Hikma Pharma and grant support from Bristol Myers‐Squibb.

Cite this